Anaheim, CA—A new process for handling oral chemotherapy medications that delineates prescriber privileges may help to avert errors or drug–drug interactions, said Brian L’Heureux, PharmD, at the American Society of Health-System Pharmacists meeting. On August 1, 2010, at Suburban Hospital [ Read More ]
For Overweight Patients, Dosing Chemotherapy Based on Total Body Weight Does Not Lead to More Toxicities
Anaheim, CA—Overweight as well as obese chemo therapy recipients who are dosed according to total body weight do not experience more adverse drug events or cycle delays than normal weight recipients. The finding, which comes from a 10- year retrospective [ Read More ]
Anaheim, CA—As first-line treatment of metastatic colorectal cancer, a regimen of leucovorin, 5-fluorouracil, and irinotecan (FOLFIRI) is more costeffective than a regimen of leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX), investigators at Northeastern Uni versity School of Pharmacy, Boston, have suggested. They [ Read More ]
Anaheim, CA—Assessing palonosetron use for the prevention of emesis associated with chemotherapy has the potential to differentiate appropriate and inappropriate use and can lead to cost-savings, said John P. Jezak, PharmD, a pharmacy practice resident at Dartmouth-Hitchcock Medical Cen – [ Read More ]
Anaheim, CA—Chemotherapy-induced nausea and vomiting (CINV) is associated with a large clinical and economic burden among patients with cancer in a hospital outpatient setting. Preventing or controlling the onset of CINV in the index chemotherapy cycle could lead to fewer [ Read More ]
Philadelphia, PA—The “one-size-fitsall” approach to current benefit designs does not recognize that health services have different levels of value; such an approach, therefore, lacks incentives for patients to adhere to diagnostic tests and treatments with proven effectiveness that may help to contain costs to various healthcare stakeholders. [ Read More ]
Philadelphia, PA—As the cost of cancer care continues to rise, payers are struggling with solutions to curtail the cost trend while maintaining value. This was the topic of the preconference session, which opened the 2-day First Annual Conference of the Association for Value-Based Cancer Care on March 29, 2011.
[ Read More ]
Philadelphia, PA—The field of oncology stands to benefit greatly from molecular diagnostic trends, according to Jane F. Barlow, MD, MPH, MBA, Vice President, Clinical Innovation, Medco Health Solutions, who offered a pharmacy benefit manager’s (PBM) perspective of the role of diagnostics, including the use of companion tests in drug development. These companion tests will represent another potential expenditure and coverage decision for PBM companies. [ Read More ]
Philadelphia, PA—Third-party oncology benefits management, tiered networks, and accountable care organizations (ACOs) are some of the trends gaining traction in the health insurance industry, according to Donald Liss, MD, Senior Medical Director, Independence Blue Cross of Philadelphia, who described cancer care from a large insurer’s perspective.
[ Read More ]
Philadelphia, PA—The National Com - prehensive Cancer Network (NCCN) is an alliance of academic cancer centers in the United States that seeks to optimize decision-making and policies for improving the delivery of appropriate and effective cancer care. [ Read More ]
Philadelphia, PA—The age of personalized cancer therapies is upon us. In oncology, personalized medicine encompasses the use of tests to determine the genes and gene interactions that can reliably predict an individual’s response to therapy or the chance of disease recurrence. The use of molecular diagnostic testing that provides the genomic profile of an individual’s tumor facilitates an understanding of some specific tumors that allows the selection of a treatment most likely to induce a response in that patient.
[ Read More ]
Philadelphia, PA—The new biologic therapy eribulin (Halaven) was recently approved by the US Food and Drug Administration for the treatment of patients with metastatic breast cancer. Stephen C. Malamud, MD, Attending Physician, Beth Israel Medical Center, New York City, discussed the benefits and risks associated with this new treatment option at a special session during the meeting.
[ Read More ]
Philadelphia, PA—Changes in oncology reimbursement have driven the consolidation of community oncology practices, as more of these practices are being squeezed financially, according to Ted Okon, BS, MBA, Executive Director, Community Oncology Alliance. Consoli dation decreases alternatives, and that means reduced competition, as many oncologists lose their practices.
[ Read More ]
Philadelphia, PA—The estimated cost for physician practices to interact with health insurance plans is $23 billion to $31 billion annually, according to a 2009 national survey conducted by Casalino and colleagues (Health Aff. 2009;28:w533-w543). [ Read More ]
Philadelphia, PA—The medically under - served population needs easier access to healthcare and tools that provide a seamless transition between all phases of the treatment process, from screening through therapy and survivorship. Payers play an important role in the future of oncology and need to be in the decision-making network.
Patient assistance and patient navigation programs aim to provide patients with reliable education to inform their decision-making, but these programs are sometimes referred to as “add-ons,” and they cost money.
[ Read More ]
Philadelphia, PA—When preparing to tackle oncology drug reimbursement concerns, it is critical to understand the benchmarks that influence reimbursement, according to John F. Aforismo, BScPharm, RPh, FASCP, Chief Executive Officer, RJ Health Systems Inter – national, Rocky Hill, CT. At [ Read More ]
Philadelphia, PA—Implementing path - ways to sustain community oncology and offering additional nursing and care management models are recent strategies being adopted by various practices and payers to reduce the medical and pharmacy costs in cancer management and improve the quality of care. [ Read More ]
Philadelphia, PA—Fragmentation in oncology care significantly influences physicians’, payers’, and patients’ understanding of how cancer therapies lead to improved quality of care. The main reason for fragmentation is the challenge in linking pharmacy and medical data in a way that generates usable information, according to Atheer A. Kaddis, PharmD, Vice President, Managed Markets, Diplomat Specialty Pharmacy. [ Read More ]
San Francisco, CA—A new, large comparative effectiveness analysis of 3 techniques for delivering radiation therapy for the treatment of localized prostate cancer supports intensity-modulated radiation therapy (IMRT) as the current standard, said Ronald Chen, MD, MPH, Assistant Professor of Radiation Oncology, University of North Carolina (UNC), Chapel Hill, and Research Fellow, Sheps Center for Health Services Research, UNC at the 2012 annual Genitourinary Cancers Symposium.[ Read More ]
San Francisco, CA—In a retrospective long-term comparative analysis of 3 prostate cancer treatment strategies, treatment with external beam radiation therapy (EBRT) was more toxic and costlier than prostatectomy and brachytherapy, according to Cleveland Clinic researchers who presented their data at the 2012 annual Genitourinary Cancers Symposium. In most other studies, the reported treatment-related toxicity data cover a follow-up period of only 5 years, said lead investigator Jay P. Ciezki, MD, Staff Physician, Cleveland Clinic. [ Read More ]
Personalized Vaccine Promising When Added to Sunitinib in Patients with Metastatic Renal-Cell Carcinoma
San Francisco, CA—A personalized form of immunotherapy added to sunitinib (Sutent) treatment prolonged survival to beyond 30 months in almost half of patients with newly diagnosed, unfavorable-risk metastatic renal-cell carcinoma (mRCC), according to the results of an open-label phase 2 study presented at the 2012 Genitourinary Cancer Symposium. Only approximately 1 in 10 patients with unfavorable-risk mRCC treated with sunitinib, the standard first-line treatment for clear-cell mRCC, survive past 30 months. [ Read More ]
San Francisco, CA—The dosage of axitinib, the standard second-line treatment for metastatic renal-cell carcinoma (mRCC), should be uptitrated in those patients who fail to achieve therapeutic blood levels on the standard 5-mg daily dosage, according to a new analysis of an international randomized trial presented at the 2012 Genitourinary Cancers Symposium. [ Read More ]
San Francisco, CA—A large number of patients with metastatic renal-cell carcinoma (mRCC) are ineligible for clinical trials and their clinical outcomes are inferior to those of patients who are trial eligible, according to a study presented at the 2012 Genitouri nary Cancers Symposium. The data were presented by the International mRCC Database Con sorti um, a group that analyzed data from 17 international cancer centers on consecutive series of patients with mRCC. Clinical trials have strict eligibility criteria to maintain internal validity. [ Read More ]
In Head-to-Head Comparison, Continuous Beats Intermittent Hormonal Therapy for Metastatic Prostate Cancer
Chicago, IL—In men with metastatic prostate cancer, especially those with minimal disease spread, continuous rather than intermittent hormonal therapy should be considered the preferred therapy, according to the results of a large multicenter phase 3 international trial.[ Read More ]
Approximately 1 in 5 patients with cancer who are undergoing radiotherapy as part of their treatment can count on unexpected hospital stays—adding an economic and clinical burden on the patient and on the healthcare system, according to an analysis by Nabeel H. Arastu, BS, and colleagues at the Brody School of Medicine at East Carolina University, Greenville, NC, which was presented at the 2012 ASCO meeting.[ Read More ]
Chicago, IL—Improved cancer screening can save lives, and despite the high cost of implementing such a measure, it was found cost-effective and therefore valuable in a recent analysis using quality-adjusted life-years (QALYs), said Michael S. Broder, MD, President of Partnership for Health Analytic Research, LLC (PHAR), CA, and colleagues, at the 2012 American Society of Clinical Oncology meeting.[ Read More ]
Tivozanib, a potent investigational tyrosine kinase inhibitor with a long half-life, demonstrated significant improvement in progression-free survival (PFS) as first-line targeted therapy for metastatic renal-cell carcinoma (RCC), according to results from a phase 3 randomized, open-label trial.
The results suggest that “tivozanib should be considered a first-line treatment option for metastatic RCC,” said Robert Motzer, MD, an oncologist at Memorial Sloan-Kettering Cancer Center, New York, and the trial’s lead investigator.[ Read More ]
Chicago, IL—The surprising results of a randomized trial on patient preference for one cancer therapy over another show that patient-reported quality-of-life (QOL) differences influence treatment preference far more than physicians had imagined, suggested researchers at the 2012 American Society of Clinical Oncology meeting.[ Read More ]
Atlanta, GA—The new oral tyrosine kinase inhibitor (TKI) ponatinib (Iclusig) has significant activity and is well tolerated in patients with highly pretreated chronic myeloid leukemia (CML) or with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) who otherwise lack therapeutic options. Twelve-month follow-up data from a pivotal phase 2 trial of ponatinib in this population were reported by Jorge E. Cortes, MD, Professor of Medicine and Deputy Chair, Department of Leukemia, at M.D. [ Read More ]
Atlanta, GA—Ruxolitinib (Jakafi) alleviates symptoms such as fever, headache, weight loss, and fatigue, and reduces spleen size in patients with myelofibrosis. This finding, by the French Intergroup of Myeloproliferative Neoplasms (FIM), confirms those from the COMFORT-I and COMFORT-II trials, in which significant reductions in spleen volume were observed with ruxolitinib at weeks 24 and 48.[ Read More ]
Orlando, FL—A personalized immunotherapy (AGS-003) in conjunction with sunitinib (Sutent) nearly doubled the expected progression-free survival (PFS) and overall survival (OS) in patients with unfavorable-risk metastatic renal-cell carcinoma (RCC), according to results from a single-arm phase 2 trial.[ Read More ]
Chicago, IL—Inappropriate deviation from evidence-based standards of care for cancer raises costs in excess of $25,000 per patient, stated Arlene A. Forastiere, MD, Senior Vice President of Medical Affairs at eviti, Inc, Philadelphia, PA, in a poster presented at the 2013 American Society of Clinical Oncology annual meeting.
In Dr Forastiere’s review of oncology treatment plans for 2544 patients, approximately 25% of the patients had treatment plans that did not conform to evidence-based standards.[ Read More ]
Chicago, IL—Adding bevacizumab (Avastin) to standard chemotherapy improves overall survival (OS) in women with metastatic or relapsed cervical cancer, representing the first instance in which a targeted therapy has significantly prolonged OS in this patient population.[ Read More ]
Chicago, IL—The use of costly diagnostic imaging of uncertain value is increasing rapidly for patients with localized non–small-cell lung cancer (NSCLC), according to data from the Surveillance, Epidemiology and End Results (SEER)-Medicare database. Frequent surveillance imaging was found for white patients and for those with higher socioeconomic status, despite lack of evidence for its value and its high cost, said Jason D. [ Read More ]
Chicago, IL—“Building Bridges to Conquer Cancer” was the theme of the 2013 American Society of Clinical Oncology (ASCO) annual meeting, as well as of the address of ASCO’s outgoing President Sandra M. Swain, MD.
Dr Swain’s address focused on 3 pillars of the theme: (1) ensuring global health equity, (2) the need to strengthen future generations of leaders and providers, and (3) the vision for a rapid learning system in oncology. These 3 issues “belong squarely on our personal and professional radar screens,” she said.[ Read More ]
Chicago, IL—Removing copays may help boost mammography screening rates for all age-groups above age 40 years. One insurer found a significant increase in screening rates with the removal of a copay, said Jeffrey M. Peppercorn, MD, MPH, Medical Oncologist at Duke Cancer Institute, Durham, NC.
A significant number of middle-aged women who live in rural locales do not pursue even biennial breast cancer screening, and cost may play a role, according to insurance claims data Dr Peppercorn presented at ASCO 2013.[ Read More ]
Chicago, IL—The number of oral oncolytic drugs has increased dramatically, but despite increased convenience, there is growing concern regarding adherence, said Winson Y. Cheung, MD, MPH, Assistant Professor, University of British Columbia Division of Medical Oncology, Vancouver, at a session on adherence at ASCO 2013. “Oral drugs shift the onus of treatment adherence from healthcare providers to patients,” Dr Cheung said.[ Read More ]
Chicago, IL—Hospitalizations and readmissions add substantial costs to healthcare. The annual cost of 30-day hospital readmissions in the United States is estimated to be $16 billion. In addition, bundled payment models may eliminate additional payment for readmissions in a specified period after discharge.
Several poster presentations at ASCO 2013 explored factors associated with readmission or unplanned hospitalizations in patients with cancer.[ Read More ]
Chicago, IL—The rate of therapy for localized prostate cancer does not increase in markets with higher penetration of robotic surgical technology and intensity-modulated radiation therapy (IMRT), according to an examination of trends using the Surveillance, Epidemiology and End Results (SEER)-Medicare–linked database, according to a poster presentation at the 2013 American Society of Clinical Oncology meeting by lead investigator Florian Rudolf Schroeck, MD, MS, Clinical Lecturer, Urology, University of Michigan, Ann Arbor.[ Read More ]
Symptoms of neuropathy may be evident a decade or more after completion of chemotherapy regimens that had been for the treatment of patients with colorectal cancer (CRC), reported researchers from Tilburg University in the Netherlands. Their recent study (Mols F, et al. J Clin Oncol. 2013;31:2699-2707) was supported by the Netherlands Organization for Scientific Research and the Dutch Cancer Society.[ Read More ]
Chicago, IL—Advances in the understanding of the biology of multiple myeloma and the identification of new drugs have resulted in improved management of myeloma, including for disease refractory to the recent proteasome inhibitors and immunomodulatory agents that have been added to the treatment of patients with myeloma.
New therapeutic strategies are needed in this challenging population, said Robert Z. Orlowski, PhD, MD, Professor, Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center, Houston, TX, at the 2013 American Society of Clinical Oncology annual meeting.[ Read More ]
Redesigning Clinical Trials Necessary to Enhance Discovery of Effective Targeted Drugs in the Genomic Era
Boston, MA—Defining optimal therapeutic efficacy in the genomic era will require that clinical trial design in oncology move from a drug-centric approach to a patient-centric one. Retrofitting current knowledge into old paradigms will slow the progress in discovering effective targeted agents, said Razelle Kurzrock, MD, Director, Center for Personalized Therapy and Clinical Trials, Moores Cancer Center, University of California, San Diego, at the Global Biomarkers Consortium Second Annual Conference.[ Read More ]
Boston, MA—Diagnosing lung cancer by swabbing a patient’s nose may be possible in the not-too-distant future. Changes in nasal gene expression in patients with lung cancer have been found to correlate with changes in gene expression in the bronchus, opening the door to the possibility of nasal gene expression as an early diagnostic biomarker of lung cancer, said Avrum Spira, MD, MSc, Director, Translational Bioinformatics Program, Boston University Clinical and Translational Science Institute.[ Read More ]
Boston, MA—Incorporating personalized medicine into everyday oncology clinical practice will require new paradigms in an effort to match patients with cancer with the appropriate therapies, as well as attempts to treat solid tumors at an earlier stage with targeted agents, said Razelle Kurzrock, MD, Director, Center for Personalized Cancer Therapy, University of California, San Diego (UCSD) Moores Cancer Center, at the Second Global Biomarkers Consortium annual conference.[ Read More ]
Boston, MA—Next-generation sequencing is a valuable tool to identify actionable genomic alterations that may be present in a tumor sample, said Gary A. Palmer, MD, JD, MBA, MPH, Senior Vice President of Medical Affairs and Commercial Development, Foundation Medicine, Cambridge, MA, at the Second Global Biomarkers Consortium annual conference.[ Read More ]
New Orleans, LA—Novel options for the treatment of patients with hematologic conditions are in the pharmaceutical pipeline, with many drugs showing promising results. Here is a look at key studies presented at the 2013 American Society of Hematology annual meeting.
Chronic Lymphocytic Leukemia
Phase 3 studies of idelalisib demonstrated impressive progression-free survival (PFS) in previously treated patients with chronic lymphocytic leukemia (CLL).
New Orleans, LA—The use of decitabine (Dacogen) is more cost-effective than conventional induction therapy for patients aged >60 years with acute myeloid leukemia (AML), according to data from a recent economic analysis.[ Read More ]
New Orleans, LA—Recipients of allogeneic hematopoietic cell transplant are at high risk for financial burden, according to survey-based data collected by Nandita Khera, MD, MPH, a medical oncologist from the Blood and Marrow Transplant Program, Mayo Clinic Arizona, Phoenix, and colleagues.
The reasons include prolonged hospital stays, living away from home, high out-of-pocket (OOP) costs, extended duration of work loss for the patient and caregiver, and the occurrence of chronic medical problems, including complications from the transplant.
New Orleans, LA—More patients with diffuse large B-cell lymphoma (DLBCL) are receiving rituximab infusions in the hospital setting, incurring greater costs than those receiving infusions in the office or clinic, an examination of medical and pharmacy claims has shown.
Rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is the recommended first-line therapy for DLBCL, improving overall survival compared with CHOP alone.[ Read More ]
New Orleans, LA—New research has confirmed that 30-day readmission for reduced-toxicity conditioning allogeneic hematopoietic-cell transplantation (allo-HCT) is linked to greater 100-day posttransplant hospital charges.
The finding justifies 30-day readmission as a significant marker of quality of care, said lead investigator Sherri Rauenzahn, MD, a palliative care fellow at West Virginia University in Morgantown, who presented her data at ASH 2013.[ Read More ]
New Orleans, LA—Peripheral T-cell lymphoma (PTCL) is associated with high resource utilization rates and high overall costs, according to a multicenter study presented at ASH 2013. Hospitalizations, in particular, represent a major clinical and economic burden, indicating the need for treatments requiring lower resource utilization with better PTCL management.[ Read More ]
New Orleans, LA—Those frustrated with low long-term remission rates in adult patients with acute lymphocytic leukemia (ALL) can find hope in the superior outcomes associated with treatment for pediatric ALL. Overall survival (OS) with therapy reaches 85% in children but lags in adults at 45%. Targeting specific pathways and adding novel agents to standard therapy should improve outcomes in adult patients.[ Read More ]
Adjuvant Chemotherapy Benefit in Stage II Colon Cancers Is Small, May Even Cause Harm, Depending on Prognostic Markers
San Francisco, CA—The majority of patients with stage II colorectal cancer (CRC) have a good prognosis with surgery and gain little with adjuvant chemotherapy, said Richard M. Goldberg, MD, Physician-in-Chief, Ohio State University Comprehensive Cancer Center, Columbus, OH, at the 2014 Gastrointestinal Cancers Symposium.[ Read More ]
San Francisco, CA—Many molecularly targeted agents that inhibit different pathways of hepatocarcinogenesis are under development, and novel targets are being assessed in hepatocellular carcinoma (HCC), said Andrew X. Zhu, MD, PhD, Director, Liver Cancer Research, Massachusetts General Hospital, Boston, at the 2014 Gastrointestinal Cancers Symposium. [ Read More ]
New Orleans, LA—The efficiency of rituximab (Rituxan) and the associated cost can be improved by switching from intravenous (IV) to subcutaneous (SC) administration. Such a switch led to a substantial reduction in patient chair time and in active healthcare professional time, said Christof Wiesner, PhD, MPH, of the Market Access Department, Genentech, San Francisco, CA, at the ASH 2013 meeting. [ Read More ]
Boston, MA—Incorporating genomics into the practice of medicine requires the demonstration of the ability of biomarkers to impact clinical decision-making, and ensuring that patients receive the best therapy based on genomic findings. Scott A. Tomlins, MD, PhD, Assistant Professor of Pathology and Urology, University of Michigan Medical School, Ann Arbor, reviewed efforts to realize genomic medicine into prostate cancer diagnosis and management at the second Global Biomarkers Consortium annual conference. [ Read More ]
Boston, MA—Biomarker development and validation are essential for the rational use of emerging cancer treatments, said presenters at the second Global Biomarkers Consortium annual conference. [ Read More ]
Hollywood, FL—The Affordable Care Act (ACA) is in its infancy, but it is already changing oncology practice, said panelists at the 2014 National Comprehensive Cancer Network (NCCN) Conference roundtable discussion. The consequences of the ACA include the changing composition of oncology patients, the risk pool of the exchanges, new payment and reimbursement models, acquisition fever, and oncology workforce demands, the panelists said. [ Read More ]
San Francisco, CA—Phase 3 data from a global clinical trial have demonstrated an improvement in overall survival (OS) when the investigational angiogenesis inhibitor ramucirumab is added to chemotherapy as second-line therapy in patients with advanced gastric cancer. [ Read More ]
A genomic test to sequence the circulating tumor cells (CTCs) from whole blood, ClearID Breast Cancer from Cynvenio Biosystems, is now available commercially to molecularly monitor for breast cancer recurrence. The test uses a standard blood draw from which DNA from tumor cells is isolated and interrogated using next-generation–sequencing tools to determine the presence of cancer-associated DNA mutations. [ Read More ]
Boston, MA—Combinations of targeted therapies will be key to overcoming resistance that occurs in tumor cells and leads to eventual failure of a single targeted agent, said Alex Adjei, MD, PhD, the Katherine Anne Gioia Chair in Cancer Medicine, Roswell Park Cancer Institute, Buffalo, NY, at the Second Global Biomarkers Consortium annual conference. [ Read More ]
San Francisco, CA—In routine patient care, adding bevacizumab (Avastin) to standard FOLFIRI (leucovorin, 5-fluorouracil, and irinotecan) improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC), according to data presented at the 2014 Gastrointestinal Cancers Symposium. [ Read More ]
Updated NCCN Guidelines for Non-Hodgkin Lymphoma Note Controversy Related to B-Cell Disease Management
Hollywood, FL—The updated guidelines from the National Comprehensive Cancer Network (NCCN) for the management of non-Hodgkin lymphoma (NHL) includes new strategies in the management of diffuse large B-cell lymphoma (DLBCL) and new guidelines for T-cell lymphoproliferative disorders. [ Read More ]
Updated NCCN Melanoma Guideline Adds BRAF Inhibitor and MEK Inhibitor to First-Line Targeted Therapeutic Options
Hollywood, FL—The updated National Comprehensive Cancer Network (NCCN) guidelines for the management of melanoma now include the BRAF inhibitor dabrafenib (Tafinlar) as a Category 1 recommendation for the primary treatment of patients with metastatic melanoma and BRAF mutation, as well as the use of the mitogen-activated protein kinase (MEK) inhibitor trametinib (Mekinist) for the treatment of patients with melanoma and BRAF mutation. These 2 drugs, which received US Food and Drug Administration (FDA) approval last year, are now added to the NCCN targeted therapies for the treatment of patients with advanced or metastatic melanoma. [ Read More ]
Los Angeles, CA—The Fourth Annual Conference of the Association for Value-Based Cancer Care, held May 6-9, 2014, kicked off 4 days of presentations by oncology stakeholders from across the country, including patients, physicians, pharmacists, nurses, payers, healthcare investors, and drug and diagnostics makers. [ Read More ]
Los Angeles, CA—The cost of cancer care is a major cost driver for payers, who are actively engaging in the management of this complex disease state. Payer approaches to cancer care continue to evolve, with new reimbursement methodologies key to maintaining affordability, said Gary M. Owens, MD, President, Gary Owens Associates, Ocean View, DE, and John Fox, MD, MHA, Senior Medical Director and Associate Vice President of Medical Affairs, Priority Health, Grand Rapids, MI, at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]
San Francisco, CA—New cytotoxic combinations introduced over the past several years for the treatment of advanced pancreatic adenocarcinoma now constitute the standard of care for the treatment of all stages of the disease. Eileen M. O’Reilly, MD, Gastrointestinal Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York, reviewed emerging treatments at the 2014 Gastrointestinal Cancers Symposium. [ Read More ]
Hollywood, FL—Cancer survivorship guidelines have been expanded to include the management of neuropathic pain and cancer-associated cognitive dysfunction, said speakers at the 2014 National Comprehensive Cancer Network (NCCN) meeting. [ Read More ]
Hollywood, FL—The treatment options for patients with castration-resistant prostate cancer (CRPC) have increased over the past few years. Understanding the clinical disease states is essential when choosing therapy for this patient population, according to Celestia S. Higano, MD, Professor of Medicine and Urology, University of Washington, Seattle, who described the recent additions to the therapeutic armamentarium at the 2014 National Comprehensive Cancer Network Conference. [ Read More ]
Hollywood, FL—Driver mutations, most frequently KRAS and EGFR, account for approximately 50% of non–small-cell lung cancer (NSCLC), and this recognition is shifting the NSCLC treatment paradigm toward targeted therapy when possible, said Leora Horn, MD, MSc, Assistant Professor of Medicine, Division of Hematology/ Oncology, Vanderbilt University, Nashville, TN, at the 2014 National Comprehensive Cancer Network Conference. [ Read More ]
Los Angeles, CA—Increasing complexities in diagnostic science, the development of precision medicine, and the use of targeted agents require unprecedented levels of collaboration between pharmaceutical manufacturers, government agencies, and payers, said oncology experts during a panel discussion on personalized medicine at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]
Los Angeles, CA—An agenda for personalized medicine must address quality control for test performance, billing and coding for molecular tests, and other practical challenges. [ Read More ]
Los Angeles, CA—Although targeted drug development and testing are clearly transforming medicine, resistance to greater uptake of personalized medicine includes a shift in the evidence threshold in personalized testing and drawbacks to the delivery system, including the cost of molecular tests, said Peter B. Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]
Los Angeles, CA—Worksite health centers can improve the quality and effectiveness of cancer treatment for employees while reducing costs for their employers. [ Read More ]
Los Angeles, CA—Worksite pharmacies have unique advantages over local pharmacies in caring for employees with cancer. [ Read More ]
Chicago, IL—According to a survey presented at the 2014 American Society of Clinical Oncology (ASCO) meeting, the majority of patients with cancer want to have cost-of-treatment discussions with their oncologists. And when they occur, these discussions do not lead to negative feelings in most patients. [ Read More ]
Delaying ADT for PSA-Only Relapse May Be Viable Option for Men with Prostate Cancer and PSA-Only Relapses
Chicago, IL—Delaying androgen deprivation therapy (ADT) for at least 2 years did not lead to worse overall survival or prostate cancer–specific survival compared with the initiation of ADT within 3 months of rising prostate-specific antigen (PSA) in men with PSA-only relapse (ie, biochemical relapse) after the primary treatment of prostate cancer with surgery or radiation, according to the results of a large population-based study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing. [ Read More ]
The cancer drug pipeline continues to boast many new therapies, reinforcing the recent trends of new and improved monoclonal antibodies and other classes of targeted therapies for different types of tumors. [ Read More ]
Los Angeles, CA—Patient comfort and emotional support are part of the quality components in value-based cancer care. [ Read More ]
Even When Adjusting for Improved Survival, Newer Anticancer Drugs Are More Expensive than Older Ones
Chicago, IL—Even after adjusted for improved outcomes, newer anticancer drugs are more expensive than older agents, said Rena Conti, PhD, Assistant Professor of Health Policy and Economics, University of Chicago, at the 2014 American Society of Clinical Oncology meeting. [ Read More ]
Chicago, IL—Hospital readmissions in patients with cancer reflect the high burden of this disease, which is often refractory and, therefore, readmission is not reasonably preventable. [ Read More ]
Chicago, IL—Contrary to common belief, there appears to be little demand on the part of patients with cancer for unsuitable, high-cost, low-value tests or therapies. [ Read More ]
Blue Cross Blue Shield (BCBS) is implementing value-based care and payment models across the country to reward quality and improve outcomes, and these are amounting to billions of dollars in cost-savings and reduced hospitalizations. [ Read More ]
Chicago, IL—Adjuvant exemestane is more effective at preventing breast cancer recurrences than tamoxifen when given with ovarian function suppression (OFS) in young women with hormone receptor–positive early breast cancer, reported Olivia Pagani, MD, Clinical Director, Breast Unit, Oncology Institute of Southern Switzerland, Bellinzona, at the 2014 American Society of Clinical Oncology meeting. [ Read More ]
Chicago, IL—The upfront addition of docetaxel to androgen deprivation therapy (ADT) adds more than 1 year to overall survival (OS) compared with ADT alone in men with newly diagnosed hormone-sensitive prostate cancer, according to findings from a phase 3 study presented at the 2014 American Society of Clinical Oncology meeting. [ Read More ]
Los Angeles, CA—Targeted therapies have dramatically increased their share of global oncology sales over the past decade. But concerns over value have led to more payer scrutiny of targeted therapies and other oncology drugs, suggested Doug Long, Vice President, Industry Relations, IMS Health, at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]
Los Angeles, CA—IBM Watson computer is changing the face of oncology practice through its massive parallel computing system, utilizing natural language processing and cognitive machine computing. Unlike HAL 9000 from the movie 2001: A Space Odyssey, the IBM Watson system does not interpret the results but rather builds on information it receives from previous operations and offers possible solutions to new queries, said Mark G. Kris, MD, William and Joy Ruane Chair, Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]
Los Angeles, CA—CancerLinQ is focused on improving quality of cancer care and enhancing outcomes by providing patients and providers real-time access to big data in a rapid electronic system, said George W. Sledge, Jr, MD, Chief, Division of Oncology, Stanford University Medical Center, CA. [ Read More ]
Los Angeles, CA—Value is the preeminent goal in cancer care, because it unites all of the interests of the stakeholders, including patients, said Douglas W. Blayney, MD, Medical Director, Stanford Cancer Institute, CA, at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]
Chicago, IL— Necitumumab, a human immunoglobulin G1 anti-EGFR monoclonal antibody, added to standard chemotherapy significantly improved survival compared with chemotherapy alone as first-line treatment of patients with stage IV non–small-cell lung cancer (NSCLC) of squamous histology. [ Read More ]
Chicago, IL—Oncologists should become value-based providers by eliminating unnecessary tests, prescribing cheaper alternatives when therapeutic equivalents exist, and keep calling for payment reform, said Ezekiel J. Emanuel, MD, PhD, Chair, Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, at the 2014 American Society of Clinical Oncology meeting, during a session on defining value from different stakeholder perspectives. [ Read More ]
Los Angeles, CA—An understanding of the genomic drivers of cancer and linking therapy to these genetic alterations provides value to all stakeholders, including oncologists, payers, researchers, and patients, said Gary Palmer, MD, JD, MBA, MPH, Senior Vice President of Medical Affairs at Foundation Medicine. [ Read More ]
Chicago, IL—With finite healthcare resources, do physicians have a duty to serve society broadly by being responsible stewards of those shared resources, or is their obligation to the patients before them incompatible with any rationing? [ Read More ]
Chicago, IL—Comparative effectiveness research (CER) and cost-effectiveness analyses have helped to define value as it relates to gynecologic oncology, said speakers during an education session on maximizing value and quality in gynecologic cancer care, at the 2014 American Society of Clinical Oncology meeting. [ Read More ]
Los Angeles, CA—Predictive testing offers greater value over prognostic testing to most stakeholders in cancer care, because it has a direct impact on disease treatment rather than simply predicting the course of the disease (which is, ironically, the role of prognostic testing), said S. Macey Johnson III, MBA, Vice President, Managed Care and Reimbursement, bioTheranostics, San Diego, CA, at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]
Improving the Value Paradigm in Drug Development Will Require More Efficient Clinical Trials, New Biomarkers
Los Angeles, CA—Much remains to be done to usher in the era of personalized healthcare, including better methods of drug development, said presenters at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]
Los Angeles, CA—Payers are scrambling to devise effective strategies to cope with rapidly changing access to quality cancer care as a result of escalating costs. At the Fourth Annual Conference of the Association for Value-Based Cancer Care, John Fox, MD, MHA, Associate Vice President of Medical Affairs at Priority Health, Grand Rapids, MI, tackled changing access and payer challenges in oncology. [ Read More ]
Los Angeles, CA—Comparative effectiveness research (CER) can be beneficial to determining value in cancer therapies, but challenges remain in applying this approach in oncology. [ Read More ]